Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)
Dateline City:
KENILWORTH, N.J.
Fourth Designation for KEYTRUDA Follows Breakthrough Status in Advanced Melanoma, Non-Small Cell Lung Cancer, and Colorectal Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab),
the company’s anti-PD-1 therapy, for the treatment of patients with
relapsed or refractory classical Hodgkin lymphoma (cHL). This is the
fourth Breakthrough Therapy Designation granted for KEYTRUDA.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Hodgkin Lymphoma Keytruda MSD NYSE:MRK Source Type: news
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Food and Drug Administration (FDA) | Lung Cancer | Lymphoma | Melanoma | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals | Skin Cancer